Accustem Sciences Inc.
1.2389+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · ACUT · USD
Key Stats
Market Cap
19.91MP/E (TTM)
-Basic EPS (TTM)
-0.12Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
AccuStem Sciences posted a Q2 net loss of $401,403, up 44% year-over-year from $278,225, driven by higher research and development costs for patent work and lab consulting, while general and administrative expenses climbed 44% on payroll from added headcount. For the half-year, the net loss widened 5% to $841,811, with R&D up 36% but G&A steady at 2% growth. Cash burn eased to $268,615 from operations, thanks to related-party advances boosting the balance to $31,341, yet liquidity strains persist amid a $2.5 million working capital deficit. Stock issuance added nearly 4 million shares, diluting ownership but funding progress toward MSC and StemPrintER launches. No revenue yet, but validation data strengthens the path. Internal controls faltered on resource gaps. Competition from larger diagnostics firms looms large.
10-Q
Q1 FY2025 results
AccuStem Sciences narrowed its Q1 FY2025 net loss to $440k from $527k a year earlier, trimming operating expenses 16% y/y to $440k while R&D ticked up 22% to $28k on lab and consulting work. General and administrative costs dropped 18% to $412k, thanks to leaner headcount, yet the firm issued nearly 4 million new shares for $1.6M in funding to bolster its $36k cash pile and $1.5M advance for an intangible asset. No revenue yet, but the team pushes toward 2026 launches of MSC lung nodule tests and StemPrintER breast cancer assays under CLIA rules. Cash burn persists; related-party advances keep it afloat. Competition from bigger diagnostics players looms large.
10-K
FY2024 results
AccuStem Sciences reported a narrowed net loss of $1.5 million for FY2024 ended December 31, 2024, down 27% from $2.1 million in 2023, driven by reduced general and administrative expenses amid ongoing clinical development of its MSC and StemPrintER genomic tests. With no revenue yet, the company advanced key milestones, including a partnership with EmeritusDx for lab processing and transfer of assays, positioning for CLIA certification and U.S. launch within 12 months; Q4 saw steady R&D spend of $138K annually, reflecting sequential stability in preclinical validation efforts without quarterly breakdowns disclosed. Liquidity remains tight at $5K cash, supported by $781K in related-party advances, while $3.4M in payables highlight funding needs for commercialization. No annual guidance issued, but management eyes $6.3B U.S. market potential. Ongoing net losses raise going-concern doubts, potentially stalling test launches if financing falters.
8-K
Auditor appointment announced
AccuStem Sciences appointed Mercurius LLP as its independent registered public accounting firm on June 17, 2024, replacing the prior auditor. No consultations occurred with Mercurius beforehand on accounting principles, audit opinions, disagreements, or reportable events during 2022-2023 or through the appointment date. This switch signals a clean transition. Routine auditor changes like this rarely disrupt operations.
10-Q
Q3 FY2024 results
AccuStem Sciences narrowed its Q3 operating loss to $328K from $599K a year earlier, while YTD through September 30, 2024, the loss shrank 37% to $1.1M versus $1.8M in 2023, driven by a 49% drop in general and administrative expenses to $297K amid headcount cuts and cost controls, though research and development rose 57% to $31K on patent and lab work. No revenue yet, but EPS improved to $(0.03) from $(0.05), confirmed against 11.3M diluted shares with anti-dilution from options and warrants excluded. Cash ticked up to $37K, propped by $781K in related-party advances offsetting $664K operating burn; a $58K note payable matures March 2025 at 7.99%. Technology transfer for StemPrintER advances with partner EmeritusDx toward CLIA certification. Yet funding remains tight, with liquidity insufficient for 12 months without new capital.
ADPT
Adaptive Biotechnologies Corpor
16.80-0.10
ADVB
Advanced Biomed Inc.
0.46+0.01
APDN
Applied DNA Sciences, Inc.
5.62+1.35
BIAF
bioAffinity Technologies, Inc.
2.48-0.01
CSTL
Castle Biosciences, Inc.
23.74-0.41
EXAS
Exact Sciences Corporation
62.74-0.56
NSTM
NovelStem International Corp.
0.02+0.00
PRPO
Precipio, Inc.
20.66-0.34
VCYT
Veracyte, Inc.
35.41-0.19
YDES
YD Bio Limited
13.24-2.56